- GC Biopharma signed an agreement with Curevo Vaccine to manufacture amezosvatein (CRV-101), a recombinant shingles vaccine under development.
- The deal gives GC Biopharma contract manufacturing rights for part of the product’s commercial supply for global markets.
GC Biopharma has announced an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (CRV-101), a recombinant shingles vaccine currently in clinical development. Under the terms of the deal, GC Biopharma will produce part of the commercial supply of amezosvatein for international markets.
The shingles vaccine market has expanded rapidly in recent years, led by GSK’s Shingrix, which accounted for more than 90% of global sales in 2024. Since its launch in 2018, the market has grown from KRW 1 trillion in 2017 to around KRW 6 trillion (USD ~4.4 billion) in 2024.
Amezosvatein is an adjuvanted recombinant protein vaccine designed to offer a differentiated tolerability profile compared with the current market leader. The vaccine uses a synthetic adjuvant aimed at reducing both local and systemic reactions to levels similar to those seen with conventional vaccines.
In early Phase 2 trials, the candidate demonstrated non-inferior immune activity compared with the leading competitor and favourable tolerability results. Curevo Vaccine is now conducting an expanded Phase 2 study in 640 adults aged 50 and older, with plans to complete it by 2026 before progressing directly to Phase 3 trials.
“This agreement marks a critical milestone in securing long-term growth drivers for GC Biopharma. We will continue to expand our global vaccine business through strategic collaborations and differentiated technologies.”
Huh Eun-Chul, CEO of GC Biopharma
